Article: Study results from Johnson & Johnson provide new insights into colon cancer risk factors.(Report)

Research findings, 'Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer,' are discussed in a new report. "The 5-year survival rate for patients with Stage II colon cancer is approximately 75%. However, there is no clinical test available to identify the 25% of patients at high risk of recurrence," researchers in the United States report (see also Colon Cancer Risk Factors).

"We have previously identified a 23-gene signature that predicts individual risk for recurrence. The present study tested this gene signature in an independent group of 123 Stage II patients, and the 23-gene signature was highly informative in ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!